Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
• 6 min read
• Published on 1 August 2025
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
View the full Basket:Beyond The Patent Cliff: Pharma's New Growth Engines
For as long as I can remember, the 'patent cliff' has been the great bogeyman of the pharmaceutical world. It’s the moment a company’s blockbuster drug, its golden goose, loses legal protection and gets swamped by a sea of cheap generic copies. The story was always the same. Revenues would fall off a cliff, executives would panic, and investors would run for the hills. It was seen as an inevitable, terrifying part of the industry’s life cycle.
And then along came AbbVie, a company that was supposed to be the poster child for this very disaster. Its drug, Humira, was the best selling medicine on the planet. When its patent expired, the script was written. Yet, AbbVie decided not to read it. Instead of collapsing, the company actually raised its profit outlook. It seems the bogeyman might not be so scary after all, provided you have a plan.
View the full Basket:Beyond The Patent Cliff: Pharma's New Growth Engines
So, what happened? Did AbbVie discover some sort of corporate magic? Not quite. The answer is far more interesting, and frankly, more reassuring for a pragmatic investor. For years, whilst Humira was printing money, AbbVie was quietly pouring billions into its research pipeline, developing the next generation of treatments.
When Humira’s day of reckoning finally arrived, two new drugs, Skyrizi and Rinvoq, were already waiting in the wings. Their sales surged, more than making up for the decline in the older drug. This wasn't a story of survival, it was a masterclass in succession planning. AbbVie didn't just dodge the bullet, it reloaded with something better. To me, this signals a fundamental shift. The patent cliff is no longer an endpoint, but a transition point for the smartest companies in the sector.
View the full Basket:Beyond The Patent Cliff: Pharma's New Growth Engines
This episode provides a clear blueprint for what a modern, resilient pharmaceutical giant should look like. The strategy is simple in theory, but fiendishly difficult in practice. It involves having the discipline and foresight to invest heavily in research and development, even when your current cash cow is performing beautifully. It’s about playing the long game, not just milking the present.
Of course, not every company has the scientific muscle or the deep pockets to pull this off. Some will inevitably stumble. But for investors, this creates a fascinating dynamic. It’s no longer about just backing a company with one blockbuster drug. It’s about identifying the firms with a proven ability to innovate and build a pipeline that can weather these storms. Think of Pfizer, with its sprawling pipeline covering everything from cancer to rare diseases, or Vertex, which has built a formidable fortress by specialising in specific, complex conditions. They understand that the future isn't about protecting one castle, it's about building an empire.
View the full Basket:Beyond The Patent Cliff: Pharma's New Growth Engines
The market seems to be catching on. Regulators and healthcare systems are increasingly rewarding genuine innovation over cheap imitation. A truly groundbreaking treatment that offers better patient outcomes can still command a premium price, creating a powerful incentive for companies to focus on real scientific progress. The game is changing from a defensive crouch to an offensive sprint towards the next discovery.
This changes how we should view the sector. The challenge is to find those companies with the right combination of a strong pipeline, proven development skills, and a strategic approach to their product lifecycle. It’s this very thinking that has led analysts to group together promising companies in this space, creating investment themes like Beyond The Patent Cliff: Pharma's New Growth Engines which focuses on firms with the potential to replicate this success.
However, let’s not get carried away. Investing in pharmaceuticals will always carry significant risks. Drug development is a high stakes game of chance. Clinical trials can, and often do, fail at the final hurdle. Regulatory approval is never a given, and a company’s multi billion dollar bet can evaporate overnight. This is not a sector for the faint of heart, and thorough research is non negotiable.
View the full Basket:Beyond The Patent Cliff: Pharma's New Growth Engines
View the full Basket:Beyond The Patent Cliff: Pharma's New Growth Engines
View the full Basket:Beyond The Patent Cliff: Pharma's New Growth Engines
View the full Basket:Beyond The Patent Cliff: Pharma's New Growth Engines
View the full Basket:Beyond The Patent Cliff: Pharma's New Growth Engines
View the full Basket:Beyond The Patent Cliff: Pharma's New Growth Engines
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article